Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fraxinus americana pollen is an allergenic extract derived from the pollen of the white ash tree (Fraxinus americana). It is a biologic product used for both diagnosing and treating allergies to this specific pollen. For diagnosis, it is administered via skin testing (percutaneous or intradermal). For treatment, it is used in immunotherapy (also known as hyposensitization or allergy shots) administered subcutaneously. The therapy works by gradually exposing the patient's immune system to the allergen, which induces immune tolerance. This process involves a shift in the immune response, including an increase in allergen-specific Immunoglobulin G (IgG) antibodies and a decrease in specific Immunoglobulin E (IgE) production, ultimately reducing the severity of allergic symptoms upon natural exposure. The product is marketed by companies such as ALK-Abello, Inc. and Greer Laboratories, Inc. as a non-standardized allergenic extract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fraxinus americana pollen extract.